Predicting Survival in Bevacizumab-Treated Colorectal Cancer: Personalized Mathematical Models Based on Clinical and Angiogenic Biomarkers
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199332 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Diana Cornelia Moisuc und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Biomarkers, Tumor, Neovascularization, Pathologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Romanian Ministry of Research, Innovation and Digitization, CNCS-UEFISCDI, Romanian Ministry of Research, Innovation and Digitization, CNCS-UEFISCDI.
Abstract (Originalsprache)
Aberrant activation of proangiogenic signaling pathways, particularly the vascular endothelial growth factor (VEGF) axis, drives neovascularization and tumor progression in colorectal cancer (CRC). Bevacizumab targets VEGF-A-mediated angiogenesis, but the lack of validated predictive biomarkers limits personalized treatment. In this prospective study, we evaluated a panel of circulating angiogenic biomarkers combined with clinical parameters, using mathematical models to predict survival in metastatic CRC patients treated with bevacizumab and chemotherapy. Low VEGF-A and VEGF-D levels, together with high bFGF, were associated with improved overall survival (OS). A logistic regression model incorporating these biomarkers, regional lymph node invasion, and primary tumor resection status showed significant prognostic accuracy (p < 0.001). Incorporating CypA further refined the model, identifying patients with low VEGF-A, VEGF-D, and CypA, and high VEGF-C and PlGF, as having the most favorable OS. These findings demonstrate that integrating clinical and circulating biomarker data can improve individualized risk assessment and support personalized therapeutic strategies for CRC patients receiving bevacizumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
- Department of Oncology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
- Department of Oncology, Regional Institute of Oncology, 700483 Iasi, Romania.
- Immunology Laboratory, "St. Spiridon" Clinical County Hospital, 700106 Iasi, Romania.
ORCID-Profile: Diana Cornelia Moisuc, Mihai Vasile Marinca, Daniela Constantinescu, Petru Cianga, Mariana Pavel-Tanasa
Förderung
- the Romanian Ministry of Research, Innovation and Digitization, CNCS-UEFISCDI
- Romanian Ministry of Research, Innovation and Digitization, CNCS-UEFISCDI
Zitieren
APA
Moisuc, D. C., Marinca, M. V., Gafton, B., Constantinescu, D., Cianga, P., & Pavel-Tanasa, M. (2025). Predicting Survival in Bevacizumab-Treated Colorectal Cancer: Personalized Mathematical Models Based on Clinical and Angiogenic Biomarkers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199332
Vancouver
Moisuc DC, Marinca MV, Gafton B, Constantinescu D, Cianga P, Pavel-Tanasa M. Predicting Survival in Bevacizumab-Treated Colorectal Cancer: Personalized Mathematical Models Based on Clinical and Angiogenic Biomarkers. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199332
BibTeX
@article{Moisuc2025,
author = {Moisuc, Diana Cornelia and Marinca, Mihai Vasile and Gafton, Bogdan and Constantinescu, Daniela and Cianga, Petru and Pavel-Tanasa, Mariana},
title = {Predicting Survival in Bevacizumab-Treated Colorectal Cancer: Personalized Mathematical Models Based on Clinical and Angiogenic Biomarkers},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199332}
}
EUVIMED